(BFM Stock Exchange) – The titles of European laboratories fall while the United States plan to announce “important” customs duties on imports of pharmaceutical products, hitherto exempt. Sanofi accuses by far the strongest drop in CAC 40, this Wednesday, April 9.

The customs pressure rises from a notch this Wednesday, April 9. The new customs salvo applied to all other countries has just come into force, with in particular a vertiginous rate of 104% customs duties for China.

On his momentum, Donald Trump does not intend to interrupt his customs overbirth of any time. During the night of Tuesday to Wednesday, the American president said that he had to introduce “major customs duties on pharmaceutical products” during an annual dinner organized by the National Republican Committee of Congress.

“Once we have done this, they will return en masse to our country, because we are the largest market,” added Donald Trump. “The advantage we have on everyone is that we are the big market,” he continued.

These latter announcements illustrate the unpredictability of the American leader even more. Pharmaceutical products were previously excluded from the first series of “reciprocal” customs measures announced on Wednesday April 2.

On the stock market, this flip-flop has the effect of a bomb for the European pharmaceutical industry. In Paris, Sanofi fell by 5.4% and accused the highest drop in CAC 40 this Wednesday morning. However, the French group is very exposed to the American market. It had achieved 45% of its turnover in the United States in 2023, Sanofi.com/assets/dotcom/content-app/publications/financial/2024-document-cré registration–2024.pdf”>According to the company’s universal document of the company.

On the London side, GSK restores 5% while Astrazenca drops almost 5.5%. The titles of the Swiss pharmaceutical laboratories are not to be outdone, Roche and Novartis give more than 5%, while in Frankfurt, Sartorius gives 3.8%, Bayer loses 3%, when Merck gives 2.7%restores

Indian industry also accuses the blow while the United States is its largest market. Last year, India exported nearly $ 13 billion in medicines, including many generics, recalls the New York Times.

This warning stroke spread to the Indian scholarship and especially to the listed values ​​of this industry. On the Bombay Stock Exchange, Glenmark restores 6%, IPCA Laboratories sold 5.3%, the bioconologies company Biocon lost 4.8%when Auropharm and Tornpharm bend by more than 3%.

Relocate production to the United States

Donald Trump finally wants to put this industry in step and encourage him to make his production relocated to the United States. In the past, he had already campaigned for “pharmaceutical companies to return (in the United States), because if they do not do so, they will have to pay an important tax,” said UBS in a note published last week.

The American president has not yet specified the magnitude of the customs prices which he wishes to apply to this category of goods. The Swiss bank had already imagined three scenarios in the event of ads of this type. According to her, Trump could add a distinct series of customs duties targeting specifically the pharmaceutical industry, or opt for a progressive approach to customs duties.

In the worst case, even if this scenario appears to him as the least likely, UBS plans that Donald Trump can choose to act on transfer prices in his “One, Big Beautiful (Tax) Bill”, only one large and beautiful tax law). That is to say to act on the taxation of prices between companies in the same group.

In a statement published on Tuesday, the European Federation of Pharmaceutical Associations and Industries (EFPIA) alerted the president of the European Commission for the risk of exodus of European industrialists to the United States, with the establishment of American customs duties. .

“The United States is now ahead of Europe on all investor measurement criteria, whether it is the availability of capital, intellectual property, speed of approval or rewards for innovation,” it is indicated in the EFPIA document.

“In addition to the uncertainty created by the threat of customs duties, there is little incitement to invest in the European Union and important factors of relocation to the United States”, also fears the professional organization.